CompletedPhase 1NCT03207958

Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

Studying Graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Washington University School of Medicine
Principal Investigator
Iskra Pusic, M.D.
Washington University School of Medicine
Intervention
Belimumab(drug)
Enrollment
10 target
Eligibility
18 years · All sexes
Timeline
20182024

Study locations (1)

Collaborators

GlaxoSmithKline · American Cancer Society, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03207958 on ClinicalTrials.gov

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Graft versus host disease

← Back to all trials